Institution
Icahn School of Medicine at Mount Sinai
Education•New York, New York, United States•
About: Icahn School of Medicine at Mount Sinai is a education organization based out in New York, New York, United States. It is known for research contribution in the topics: Population & Cancer. The organization has 37488 authors who have published 76057 publications receiving 3704104 citations. The organization is also known as: Mount Sinai School of Medicine.
Topics: Population, Cancer, Transplantation, Virus, Health care
Papers published on a yearly basis
Papers
More filters
TL;DR: Level 1 CDRs have the potential to inform clinical judgment, to change clinical behavior, and to reduce unnecessary costs, while maintaining quality of care and patient satisfaction.
Abstract: Clinical experience provides clinicians with an intuitive sense of which findings on history, physical examination, and investigation are critical in making an accurate diagnosis, or an accurate assessment of a patient’s fate. A clinical decision rule (CDR) is a clinical tool that quantifies the individual contributions that various components of the history, physical examination, and basic laboratory results make toward the diagnosis, prognosis, or likely response to treatment in a patient. Clinical decision rules attempt to formally test, simplify, and increase the accuracy of clinicians’ diagnostic and prognostic assessments. Existing CDRs guide clinicians, establish pretest probability, provide screening tests for common problems, and estimate risk. Three steps are involved in the development and testing of a CDR: creation of the rule, testing or validating the rule, and assessing the impact of the rule on clinical behavior. Clinicians evaluating CDRs for possible clinical use should assess the following components: the method of derivation; the validation of the CDR to ensure that its repeated use leads to the same results; and its predictive power. We consider CDRs that have been validated in a new clinical setting to be level 1 CDRs and most appropriate for implementation. Level 1 CDRs have the potential to inform clinical judgment, to change clinical behavior, and to reduce unnecessary costs, while maintaining quality of care and patient satisfaction. JAMA. 2000;284:79-84 www.jama.com
997 citations
Roswell Park Cancer Institute1, Duke University2, Ohio State University3, Wake Forest University4, Memorial Sloan Kettering Cancer Center5, Harvard University6, University of Pennsylvania7, University of Minnesota8, Washington University in St. Louis9, University of Florida10, University of Wisconsin-Madison11, University of Chicago12, State University of New York Upstate Medical University13, Icahn School of Medicine at Mount Sinai14, Oregon Health & Science University15, University of North Carolina at Chapel Hill16, University of California, San Francisco17, University of Texas MD Anderson Cancer Center18, Medical College of Wisconsin19
TL;DR: Lenalidomide maintenance therapy, initiated at day 100 after hematopoietic stem-cell transplantation, was associated with more toxicity and second cancers but a significantly longer time to disease progression and significantly improved overall survival among patients with myeloma.
Abstract: Background Data are lacking on whether lenalidomide maintenance therapy prolongs the time to disease progression after autologous hematopoietic stem-cell transplantation in patients with multiple myeloma. Methods Between April 2005 and July 2009, we randomly assigned 460 patients who were younger than 71 years of age and had stable disease or a marginal, partial, or complete response 100 days after undergoing stem-cell transplantation to lenalidomide or placebo, which was administered until disease progression. The starting dose of lenalidomide was 10 mg per day (range, 5 to 15). Results The study-drug assignments were unblinded in 2009, when a planned interim analysis showed a significantly longer time to disease progression in the lenalidomide group. At unblinding, 20% of patients who received lenalidomide and 44% of patients who received placebo had progressive disease or had died (P<0.001); of the remaining 128 patients who received placebo and who did not have progressive disease, 86 crossed over to ...
996 citations
University of California, San Francisco1, University of Birmingham2, University of Liège3, Advocate Lutheran General Hospital4, Kantonsspital St. Gallen5, University of Adelaide6, Baylor College of Medicine7, Mayo Clinic8, University of Southern California9, Asahikawa Medical University10, University of Dundee11, Pontifical Catholic University of Chile12, Uppsala University13, University of Hong Kong14, Royal Adelaide Hospital15, University of Hamburg16, Sunnybrook Health Sciences Centre17, University of Minnesota18, Technische Universität München19, University of Cambridge20, University of Bologna21, Washington University in St. Louis22, Greenville Health System23, University of Bristol24, University of Ottawa25, Nagoya University26, University of Texas Southwestern Medical Center27, Shanghai Jiao Tong University28, Icahn School of Medicine at Mount Sinai29, Brigham and Women's Hospital30, Oregon Health & Science University31, University of Buenos Aires32, Duke University33, St. Elizabeth's Medical Center34, Dartmouth College35, University of Massachusetts Amherst36, University of the Witwatersrand37, Ghent University Hospital38, Sun Yat-sen University39
TL;DR: The GVG proposes a new Global Anatomic Staging System (GLASS), which involves defining a preferred target artery path (TAP) and then estimating limb-based patency (LBP) resulting in three stages of complexity for intervention.
993 citations
University of Pennsylvania1, Washington University in St. Louis2, Icahn School of Medicine at Mount Sinai3, University of North Carolina at Chapel Hill4, Duke University5, Emory University6, McGill University7, Columbia University8, National Institutes of Health9, University of California, San Diego10, University of Miami11, Rutgers University12, Rush University Medical Center13, University of Washington14, Stanford University15, Food and Drug Administration16, Johns Hopkins University17, Rockefeller University18, University of Florida19, University of Pittsburgh20, University of Iowa21, Group Health Cooperative22, American Diabetes Association23
TL;DR: A growing body of evidence suggests that biological mechanisms underlie a bidirectional link between mood disorders and many medical illnesses and there is evidence to suggest that mood disorders affect the course of medical illnesses.
992 citations
TL;DR: It is shown that quiescent HSCs associate specifically with small arterioles that are preferentially found in endosteal bone marrow, indicating that arteriolar niches are indispensable for maintaining HSC quiescence.
Abstract: Cell cycle quiescence is a critical feature contributing to haematopoietic stem cell (HSC) maintenance. Although various candidate stromal cells have been identified as potential HSC niches, the spatial localization of quiescent HSCs in the bone marrow remains unclear. Here, using a novel approach that combines whole-mount confocal immunofluorescence imaging techniques and computational modelling to analyse significant three-dimensional associations in the mouse bone marrow among vascular structures, stromal cells and HSCs, we show that quiescent HSCs associate specifically with small arterioles that are preferentially found in endosteal bone marrow. These arterioles are ensheathed exclusively by rare NG2 (also known as CSPG4)(+) pericytes, distinct from sinusoid-associated leptin receptor (LEPR)(+) cells. Pharmacological or genetic activation of the HSC cell cycle alters the distribution of HSCs from NG2(+) periarteriolar niches to LEPR(+) perisinusoidal niches. Conditional depletion of NG2(+) cells induces HSC cycling and reduces functional long-term repopulating HSCs in the bone marrow. These results thus indicate that arteriolar niches are indispensable for maintaining HSC quiescence.
992 citations
Authors
Showing all 37948 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Robert Langer | 281 | 2324 | 326306 |
| Shizuo Akira | 261 | 1308 | 320561 |
| Gordon H. Guyatt | 231 | 1620 | 228631 |
| Eugene Braunwald | 230 | 1711 | 264576 |
| Bruce S. McEwen | 215 | 1163 | 200638 |
| Robert J. Lefkowitz | 214 | 860 | 147995 |
| Peter Libby | 211 | 932 | 182724 |
| Mark J. Daly | 204 | 763 | 304452 |
| Stuart H. Orkin | 186 | 715 | 112182 |
| Paul G. Richardson | 183 | 1533 | 155912 |
| Alan C. Evans | 183 | 866 | 134642 |
| John C. Morris | 183 | 1441 | 168413 |
| Paul M. Thompson | 183 | 2271 | 146736 |
| Tadamitsu Kishimoto | 181 | 1067 | 130860 |
| Bruce M. Psaty | 181 | 1205 | 138244 |